#BEGIN_DRUGCARD DB04492

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C8H15NO9S

# Chemical_IUPAC_Name:
[(2R,3S,4R,5R,6R)-5-acetamido-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxidanesulfonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
2-(Acetylamino)-2-Deoxy-4-O-Sulfo-Alpha-D-Galactopyranose

# HET_ID:
NGK

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C8H15NO9S/c1-3(11)9-5-6(12)7(18-19(14,15)16)4(2-10)17-8(5)13/h4-8,10,12-13H,2H2,1H3,(H,9,11)(H,14,15,16)/t4-,5-,6-,7-,8-/m1/s1

# InChI_Key:
InChIKey=WHCJUIFHMJFEFZ-FMDGEEDCSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4492

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
301.271

# Molecular_Weight_Mono:
301.046751773

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1OFL

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2

# Predicted_LogS:
-0.85

# Predicted_Water_Solubility:
4.29e+01 g/l

# Primary_Accession_No:
DB04492

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
440173

# PubChem_Substance_ID:
46509148

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02336

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](OS(O)(=O)=O)[C@@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:23 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
U27584

# Drug_Target_1_GenBank_ID_Protein:
1002527

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
cslB

# Drug_Target_1_Gene_Sequence:
>1521 bp
ATGAAGATGCTGAATAAACTAGCCGGATACTTATTGCCGATCATGGTGCTGCTGAATGTG
GCACCATGCTTAGGTCAGGTTGTTGCTTCAAATGAAACTTTATACCAGGTTGTAAAGGAG
GTAAAACCCGGTGGTCTGGTACAGATTGCCGATGGGACTTATAAAGATGTTCAGCTGATT
GTCAGCAATTCAGGAAAATCTGGTTTGCCCATCACTATTAAAGCCCTGAACCCGGGTAAG
GTTTTTTTTACCGGAGATGCTAAAGTAGAGCTGAGGGGCGAGCACCTGATACTGGAAGGC
ATCTGGTTTAAAGACGGGAACAGAGCTATTCAGGCATGGAAATCACATGGACCCGGATTG
GTGGCTATATATGGTAGCTATAACCGCATTACCGCATGTGTATTTGATTGTTTTGATGAA
GCCAATTCTGCTTACATTACTACTTCGCTTACCGAAGACGGAAAGGTACCTCAACATTGC
CGCATAGACCATTGCAGTTTTACCGATAAGATCACTTTTGACCAGGTAATTAACCTGAAC
AATACAGCCAGAGCTATTAAAGACGGTTCGGTGGGAGGACCGGGGATGTACCATCGTGTT
GATCACTGTTTTTTTTCCAATCCGCAAAAACCGGGTAATGCCGGAGGGGGAATCAGGATT
GGCTATTACCGTAATGATATAGGCCGTTGTCTGGTAGACTCTAACCTGTTTATGCGTCAG
GATTCGGAAGCAGAGATCATCACCAGCAAATCGCAGGAAAATGTTTATTATGGTAATACT
TACCTGAATTGCCAGGGCACCATGAACTTTCGTCACGGTGATCATCAGGTGGCCATTAAC
AATTTTTATATAGGCAATGACCAGCGATTTGGATACGGGGGAATGTTTGTTTGGGGAAGC
AGGCATGTCATAGCCTGTAATTATTTTGAGCTGTCCGAAACCATAAAGTCGAGGGGGAAC
GCCGCATTGTATTTAAACCCCGGTGCTATGGCTTCGGAGCATGCTCTTGCTTTCGATATG
TTGATAGCCAACAACGCTTTCATCAATGTAAATGGGTATGCCATCCATTTTAATCCATTG
GATGAGCGCAGAAAAGAATATTGTGCAGCCAATAGGCTTAAGTTCGAAACCCCGCACCAG
CTAATGTTAAAAGGCAATCTTTTCTTTAAGGATAAACCTTATGTTTACCCATTTTTTAAA
GATGATTATTTTATAGCAGGGAAAAATAGCTGGACTGGTAATGTAGCCTTAGGTGTGGAA
AAGGGAATCCCTGTTAACATTTCGGCCAATAGGTCTGCCTATAAGCCGGTAAAAATTAAA
GATATCCAGCCCATAGAAGGAATCGCTCTTGATCTCAATGCGCTGATCAGCAAAGGCATT
ACAGGAAAGCCCCTTAGCTGGGATGAAGTAAGGCCCTACTGGTTAAAAGAAATGCCCGGG
ACGTATGCTTTAACGGCCAGGCTTTCTGCAGATAGGGCTGCAAAGTTTAAAGCCGTAATT
AAAAGAAATAAAGAGCACTGA

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
10600383	Huang W, Matte A, Li Y, Kim YS, Linhardt RJ, Su H, Cygler M: Crystal structure of chondroitinase B from Flavobacterium heparinum and its complex with a disaccharide product at 1.7 A resolution. J Mol Biol. 1999 Dec 17;294(5):1257-69.
10618199	Tkalec AL, Fink D, Blain F, Zhang-Sun G, Laliberte M, Bennett DC, Gu K, Zimmermann JJ, Su H: Isolation and expression in Escherichia coli of cslA and cslB, genes coding for the chondroitin sulfate-degrading enzymes chondroitinase AC and chondroitinase B, respectively, from Flavobacterium heparinum. Appl Environ Microbiol. 2000 Jan;66(1):29-35.
11327856	Huang W, Boju L, Tkalec L, Su H, Yang HO, Gunay NS, Linhardt RJ, Kim YS, Matte A, Cygler M: Active site of chondroitin AC lyase revealed by the structure of enzyme-oligosaccharide complexes and mutagenesis. Biochemistry. 2001 Feb 27;40(8):2359-72.
12063249	Pojasek K, Raman R, Kiley P, Venkataraman G, Sasisekharan R: Biochemical characterization of the chondroitinase B active site. J Biol Chem. 2002 Aug 23;277(34):31179-86. Epub 2002 Jun 12.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2430

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
56323

# Drug_Target_1_Name:
Chondroitinase B

# Drug_Target_1_Number_of_Residues:
506

# Drug_Target_1_PDB_ID:
1DBO

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
>Chondroitinase B precursor
MKMLNKLAGYLLPIMVLLNVAPCLGQVVASNETLYQVVKEVKPGGLVQIADGTYKDVQLI
VSNSGKSGLPITIKALNPGKVFFTGDAKVELRGEHLILEGIWFKDGNRAIQAWKSHGPGL
VAIYGSYNRITACVFDCFDEANSAYITTSLTEDGKVPQHCRIDHCSFTDKITFDQVINLN
NTARAIKDGSVGGPGMYHRVDHCFFSNPQKPGNAGGGIRIGYYRNDIGRCLVDSNLFMRQ
DSEAEIITSKSQENVYYGNTYLNCQGTMNFRHGDHQVAINNFYIGNDQRFGYGGMFVWGS
RHVIACNYFELSETIKSRGNAALYLNPGAMASEHALAFDMLIANNAFINVNGYAIHFNPL
DERRKEYCAANRLKFETPHQLMLKGNLFFKDKPYVYPFFKDDYFIAGKNSWTGNVALGVE
KGIPVNISANRSAYKPVKIKDIQPIEGIALDLNALISKGITGKPLSWDEVRPYWLKEMPG
TYALTARLSADRAAKFKAVIKRNKEH

# Drug_Target_1_Reaction:
Eliminative cleavage of dermatan sulfate containing 1,4-beta-D-hexosaminyl and 1,3-beta-D-glucurosonyl or 1,3-alpha-L-iduronosyl linkages to disaccharides containing 4-deoxy-beta-D-gluc-4-enuronosyl groups to yield a 4,5-unsaturated dermatan-sulfate disaccharide (deltaUA-GalNAc-4S).

# Drug_Target_1_Signals:
1-25

# Drug_Target_1_Specific_Function:
Cleaves the glycosaminoglycan, dermatan sulfate

# Drug_Target_1_SwissProt_ID:
Q46079

# Drug_Target_1_SwissProt_Name:
CSLB_PEDHD

# Drug_Target_1_Synonyms:
Chondroitin B eliminase
Chondroitin B lyase
Chondroitin sulfate B lyase
Chondroitinase B precursor
EC 4.2.2.19

# Drug_Target_1_Theoretical_pI:
8.94

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB04492
